Buy Park Medi World Ltd For Target Rs.350 by Choice Institutional Equities Ltd
Growth visibility supported by disciplined expansion and improving business mix:
PARKHOSP remains well-positioned for a sustained longterm growth, underpinned by its 6,590-bed pipeline to be operational by December 2028. Additional growth drivers include its cluster-led expansion strategy, improving specialty mix, gradual shift towards a higher private-pay payer mix and healthy ARPOB growth. While the near-term margin is negatively impacted by new hospital ramp-up and one-off cost pressure, we expect these transitory headwinds to normalise over the next few quarters. Further, the recently-announced oncology drug trade-margin cap is anticipated to have a negligible impact on profitability. We forecast Revenue/EBITDA/PAT to expand at a CAGR of 28.0%/28.0%/31.4% over FY26–29E. View and valuation: Rolling forward our valuation to 18x average FY28–FY29E EV/EBITDA, we retain our 'BUY' rating with a target price of INR 350
Margin impacted by new hospital ramp-up and one-off cost pressure
* Revenue came in at INR 5.1 Bn (vs. CIE estimate of INR 5.0 Bn), up 24.6% YoY and 7.4% QoQ.
* EBITDA came in at INR 1.0 Bn (vs. CIE estimate of INR 1.3 Bn), down by 9.8% YoY and 19.3% QoQ. EBITDA margin stood at 19.9% (vs. CIE estimate of 26.2%), contracting by 758 bps YoY and 660 bps QoQ.
* PAT came in at INR 0.5 Bn (vs. CIE estimate of INR 0.9 Bn), down 33.5% YoY and 36.8% QoQ, with a PAT margin of 10.2%.
Aggressive capacity expansion backed by industry-leading capital efficiency:
PARKHOSP remains on track to increase bed capacity by ~40% in FY27, having already commissioned 680 beds while targeting another 750 beds in H2FY27. The company has 2,300 beds under execution, which will take the total capacity to 6,590 beds by December 2028, while its long-term vision of 10,000+ beds by FY33 remains intact. The expansion is projected to be funded through internal accruals, pre-empting the need for equity dilution. Supported by its cluster-led expansion model, the company has maintained an industry-leading CapEx of ~INR 30–35 lakh per bed. This disciplined capital allocation, coupled with a robust expansion pipeline, is expected to drive a sustained revenue growth, margin expansion and deeper market penetration across Tier-2 and Tier-3 cities.
Near-term headwinds remain transitory; long-term earnings outlook intact:
The management forecasts the temporary drag from newly-commissioned hospitals to moderate as occupancy ramps up and insurance empanelment is completed, while cost pressure from higher consumables and patient-service enhancements are anticipated to normalise in the coming quarters. Additionally, the recently announced oncology drug trade-margin cap is projected to have a negligible impact on profitability, owing to its government-insurance-led business model and efficient procurement practices. Combined with the expected benefit from the CGHS rate revision, healthy ramp-up of new hospitals and improving operating leverage, we forecast a revenue CAGR of 28.0% over FY26–FY29E.
Premiumisation of case mix and improving payer mix to drive sustainable margin expansion:
This quarter, high-end tertiary/quaternary specialties rose to 64% of revenue, with ARPOB up 13% YoY to INR 30,646 and ALOS improving to 5.4 days. Looking ahead, the management guided for a gradual payer-mix shift, from the current 76% government-scheme dependency towards a 70:30 government-to-cash/TPA split, over 12–18 months, supporting better realisations and a sustained margin expansion. We forecast an EBITDA CAGR of 28.0% over FY26–FY29E
For Detailed Report With Disclaimer Visit. https://choicebroking.in/disclaimer
SEBI Registration no.: INZ 000160131
